We can’t show the full text here under this license.
Abstract
A total of 25,572 participants were included across 64 trials comparing glucagon-like peptide-1 receptor agonists for type 2 diabetes treatment.
- Tirzepatide showed the greatest reduction in by 2.3% and fasting plasma glucose by 3.1 mmol/L compared to placebo.
- Semaglutide and liraglutide also reduced HbA1-c and fasting plasma glucose, but to a lesser extent.
- Significant reductions in body weight were observed with tirzepatide (9.1 kg), semaglutide (2.8 kg), and liraglutide (1.2 kg) compared to placebo.
- All treatments did not show significant differences in body mass index, blood pressure, or cholesterol levels compared to placebo.
- GLP-1 receptor agonists are associated with a higher risk of gastrointestinal symptoms; semaglutide increases the risk of hypoglycemia while liraglutide reduces it compared to traditional antidiabetic drugs.
- Tirzepatide may be more suitable for treating type 2 diabetes in individuals with obesity, while semaglutide and liraglutide could be more effective for those with normal weight.
Simplified